Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban in end-stage renal disease
2015-003132-12Phase 4Completed
- Sponsor
- UZ Leuven
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of apixaban in end-stage kidney disease (ESKD) and thromboembolism, sponsored by UZ Leuven. Primary endpoint: Inter-dialytic pharmacokinetics of apixaban. Started Jul 2015; status: completed.
02
Drugs
apixaban
03
Conditions
end-stage kidney disease (ESKD)thromboembolism
Beyond the preview
Go deeper on 2015-003132-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003132-12.